ImmunoGen, Inc.
IMGN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $108,782 | $69,856 | $132,299 | $82,271 |
| % Growth | 55.7% | -47.2% | 60.8% | – |
| Cost of Goods Sold | $176 | $0 | $114,592 | $114,522 |
| Gross Profit | $108,606 | $69,856 | $17,707 | -$32,251 |
| % Margin | 99.8% | 100% | 13.4% | -39.2% |
| R&D Expenses | $213,370 | $151,117 | $114,592 | $114,522 |
| G&A Expenses | $0 | $43,812 | $38,600 | $38,489 |
| SG&A Expenses | $116,129 | $43,812 | $38,600 | $38,489 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$994 | -$1,131 | $1,210 | $5,014 |
| Operating Expenses | $329,499 | $194,929 | $153,192 | $153,011 |
| Operating Income | -$220,893 | -$125,073 | -$135,485 | -$92,173 |
| % Margin | -203.1% | -179% | -102.4% | -112% |
| Other Income/Exp. Net | $3,347 | -$1,080 | -$21,992 | -$11,960 |
| Pre-Tax Income | -$221,711 | -$139,303 | -$44,372 | -$104,133 |
| Tax Expense | $1,218 | $0 | $22,311 | $17,960 |
| Net Income | -$222,929 | -$139,303 | -$66,683 | -$122,093 |
| % Margin | -204.9% | -199.4% | -50.4% | -148.4% |
| EPS | -0.879 | -1.081 | -0.38 | -0.82 |
| % Growth | 18.7% | -184.6% | 53.7% | – |
| EPS Diluted | -0.879 | -1.081 | -0.38 | -0.82 |
| Weighted Avg Shares Out | 253,631 | 206,147 | 176,153 | 148,311 |
| Weighted Avg Shares Out Dil | 253,631 | 206,147 | 176,153 | 148,311 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $729 | $4,424 |
| Interest Expense | $4,165 | $13,150 | $23,202 | $16,974 |
| Depreciation & Amortization | $1,783 | $2,017 | $115,802 | $26,447 |
| EBITDA | -$215,763 | -$124,187 | -$19,683 | -$65,726 |
| % Margin | -198.3% | -177.8% | -14.9% | -79.9% |